UNSPSC 51372017: Pholcodine

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LPP64AWZ7L. European Medicines Agency schedules Pholcodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09795MIG. Pholcodine generally arises in the molecular formula C23H30N2O4. The term PHOLCODINE is an International Non-Proprietary Name or INN. PHOLCODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule pholcodine under HS 29391100 and SITC 54141. As of Q4 2014, PHOLCODINE remains the US FDA Preferred Term for this commodity. Pholcodine bears US NLM identifiers UMLS ID C0070742 and NCI Concept Code C87365. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OCCN1CCOCC1)CC3)C=CC2O.

UNSPSC 51372017 Pholcodine is a Commodity code under which state and local governments procure pharmaceutical products, though the three most recent opportunities indexed under this code involve naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and OTC products rather than pholcodine specifically. State and local issuing bodies under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all posted opportunities in the past four months. The work being solicited spans pharmaceutical procurement for community health initiatives, direct-to-manufacturer prescription programs, and generic drug supply contracts through authorized wholesalers. Vendors must typically hold FDA compliance certifications, maintain specified insurance coverage (including commercial general liability and professional liability), comply with the Drug Supply Chain Security Act and current Good Manufacturing Practices, and meet E-Verify and drug-free workplace requirements.

Recent opportunities show activity concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory procurement mechanism designed to inform future formal solicitation strategy rather than commit to specific contract amounts. MMCAP, administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring proposals by March 26, 2026, with pricing weighted at 75 percent of evaluation and vendors paying a 3 percent administrative fee on all contract purchases. Vendors must maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—with chargeback systems in place.